CytoTools AG
Simbols: T5O.DE
XETRA
0.408
EURTirgus cena šodien
-4.3146
P/E koeficients
2.0710
PEG koeficients
1.84M
MRK Cap
- 0.00%
DIV ienesīgums
CytoTools AG (T5O-DE) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 5.84 | 1.8 | 0 | 1.6 | ||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | -0.2 | ||||||||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.other-current-assets | 0.27 | 0.1 | 0.1 | 0.1 | ||||||||||||||
balance-sheet.row.total-current-assets | 6.24 | 2 | 0.1 | 1.7 | ||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0.1 | ||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0.1 | ||||||||||||||
balance-sheet.row.long-term-investments | 79.62 | 19.7 | 18.2 | 20.5 | ||||||||||||||
balance-sheet.row.tax-assets | -20.16 | 0 | 0 | 20.6 | ||||||||||||||
balance-sheet.row.other-non-current-assets | 0.53 | -19.7 | -18.2 | -20.6 | ||||||||||||||
balance-sheet.row.total-non-current-assets | 79.66 | 19.7 | 18.2 | 20.6 | ||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.total-assets | 85.89 | 21.6 | 18.3 | 22.3 | ||||||||||||||
balance-sheet.row.account-payables | 0.16 | 0 | 0.1 | 0.1 | ||||||||||||||
balance-sheet.row.short-term-debt | 0 | 0 | 0.1 | 0 | ||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0.1 | 0 | ||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0.08 | - | - | - | ||||||||||||||
balance-sheet.row.other-current-liab | 0.28 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0.33 | 0.1 | 0.2 | 0.3 | ||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.total-liab | 0.77 | 0.2 | 0.4 | 0.4 | ||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.common-stock | 20.55 | 5.1 | 4 | 4 | ||||||||||||||
balance-sheet.row.retained-earnings | -86.42 | -21.4 | -20.6 | -16.6 | ||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 76.34 | 0.4 | 0.4 | 34.5 | ||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 74.59 | 37.3 | 34 | 0 | ||||||||||||||
balance-sheet.row.total-stockholders-equity | 85.05 | 21.4 | 17.9 | 21.9 | ||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 85.82 | 21.6 | 18.3 | 22.3 | ||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.total-equity | 85.05 | 21.4 | 17.9 | 21.9 | ||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 85.82 | - | - | - | ||||||||||||||
Total Investments | 79.62 | 19.7 | 18.2 | 20.3 | ||||||||||||||
balance-sheet.row.total-debt | 0 | 0 | 0.1 | 0 | ||||||||||||||
balance-sheet.row.net-debt | -5.84 | -1.8 | 0.1 | -1.6 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -0.66 | -0.8 | -4.1 | -1.8 | ||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 2.5 | 0 | ||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.change-in-working-capital | 0.01 | -0.1 | -0.1 | 0.2 | ||||||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.inventory | 0.01 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.account-payables | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.other-working-capital | 0 | -0.1 | -0.1 | 0.2 | ||||||||||||||
cash-flows.row.other-non-cash-items | 0.07 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -0.58 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | -0.1 | 0 | ||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.purchases-of-investments | 0 | -1.5 | 0 | -4.8 | ||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.other-investing-activites | -1.97 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -1.97 | -1.5 | -0.1 | -4.8 | ||||||||||||||
cash-flows.row.debt-repayment | 0 | -0.1 | 0 | 0 | ||||||||||||||
cash-flows.row.common-stock-issued | 0 | 4.4 | 0 | 0 | ||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.other-financing-activites | -0.16 | 0 | 0 | 6 | ||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -0.16 | 4.2 | 0 | 6 | ||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.net-change-in-cash | -2.72 | 1.8 | -1.7 | -0.4 | ||||||||||||||
cash-flows.row.cash-at-end-of-period | -2.72 | 1.8 | -0.1 | 1.6 | ||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 0 | 1.6 | 2 | ||||||||||||||
cash-flows.row.operating-cash-flow | -0.58 | -0.9 | -1.6 | -1.7 | ||||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | -0.1 | 0 | ||||||||||||||
cash-flows.row.free-cash-flow | -0.58 | -0.9 | -1.7 | -1.7 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0.02 | 0 | 0 | 0 | ||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 0 | 0.5 | 0.7 | ||||||||||||||
income-statement-row.row.gross-profit | 0.02 | 0 | -0.5 | -0.7 | ||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | ||||||||||||||
income-statement-row.row.operating-expenses | 0.71 | 0.8 | 1.6 | 1.1 | ||||||||||||||
income-statement-row.row.cost-and-expenses | 0.71 | 0.8 | 1.6 | 1.9 | ||||||||||||||
income-statement-row.row.interest-income | 0.02 | 0 | 0 | 0 | ||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 0 | 0 | ||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0.02 | 0 | -2.5 | 0 | ||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | ||||||||||||||
income-statement-row.row.total-operating-expenses | 0.02 | 0 | -2.5 | 0 | ||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 0 | 0 | ||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 0 | 2.5 | 0 | ||||||||||||||
income-statement-row.row.ebitda-caps | -0.68 | - | - | - | ||||||||||||||
income-statement-row.row.operating-income | -0.69 | -0.8 | -1.6 | -1.8 | ||||||||||||||
income-statement-row.row.income-before-tax | -0.66 | -0.8 | -4 | -1.8 | ||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 0 | 0 | 0 | ||||||||||||||
income-statement-row.row.net-income | -0.66 | -0.8 | -4.1 | -1.8 |
Biežāk uzdotie jautājumi
Kas ir CytoTools AG (T5O.DE) kopējie aktīvi?
CytoTools AG (T5O.DE) kopējie aktīvi ir 21607950.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir 12412.000.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 1.000.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir -0.082.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir -29.508.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir -30.361.
Kāda ir CytoTools AG (T5O.DE) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir -829837.250.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 0.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 835230.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 1081631.000.